Get the Stockscreener App
1.24
9.73%
0.11
After Hours:
1.21
-0.03
-2.42%
AEON Biopharma Inc. stock is traded at $1.24, with a volume of 165.11K.
It is up +9.73% in the last 24 hours and up +84.55% over the past month.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
See More
Previous Close:
$1.13
Open:
$1.19
24h Volume:
165.11K
Relative Volume:
0.61
Market Cap:
$15.01M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+14.81%
1M Performance:
+84.55%
6M Performance:
+48.04%
1Y Performance:
-91.80%
1-Day Range:
$1.17
$1.25
1-Week Range:
$1.0545
$1.25
52-Week Range:
$0.375
$19.32
AEON Biopharma Inc. Stock (AEON) Company Profile
Name
AEON Biopharma Inc.
Sector
Industry
Phone
(949) 354-6499
Address
5 Park Plaza, Suite 1750, Irvine
Compare AEON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
1.24 | 13.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | H.C. Wainwright | Buy |
AEON Biopharma Inc. Stock (AEON) Latest News
How AEON Biopharma Inc. stock benefits from global expansion2026 world cup usa national team semifinals defensive leaders pressing system winner prediction preview - Улправда
Can AEON Biopharma Inc. Class stock stage a strong rebound this quarter2026 world cup usa national team qualification playmakers high defensive line odds analysis preview - Улправда
Midday Stock Roundup: Rivian Down on Production Totals - Orange County Business Journal
AEON Biopharma, Inc. (AEON) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
AEON Biopharma (NASDAQ:AEON) Trading Up 5.9% – Time to Buy? - Defense World
AEON Biopharma (AEON) seeks shareholder approval for PIPE, note exchange and equity plan - Stock Titan
Will AEON Biopharma Inc. stock split attract more investorsMomentum Trading Signals & Grow Generational Wealth With Ease - bollywoodhelpline.com
Midday Stock Roundup: Shimmick Corp. climbs 14% - Orange County Business Journal
Aug EndMonth: How AEON Biopharma Inc stock benefits from global expansionWeekly Profit Recap & Risk Managed Investment Strategies - moha.gov.vn
Insider Buy: Can AEON Biopharma Inc Class stock stage a strong rebound this quarterJuly 2025 Rallies & Low Drawdown Trading Techniques - moha.gov.vn
Is AEON Biopharma Inc. Class stock bottoming after sell offBond Market & Community Verified Trade Signals - Улправда
Investor Mood: Can AEON Biopharma Inc. Class stock stage a strong rebound this quarter - Улправда
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEONAeon Biopharma Latest Stock News & Market Updates - Stock Titan
Will AEON Biopharma Inc. Class stock benefit from infrastructure billWeekly Trading Summary & Reliable Breakout Stock Forecasts - Улправда
Biopharmaceutical company offers new hires stock units over four years - Stock Titan
How AEON Biopharma Inc. Class stock compares with tech leadersJuly 2025 Technicals & Free Weekly Chart Analysis and Trade Guides - Улправда
[PRE 14A] AEON Biopharma, Inc. Preliminary Proxy Statement - Stock Titan
Midday Stock Roundup: Rivian Stock Continues to Climb - Orange County Business Journal
Is AEON Biopharma Inc. Class stock undervalued historicallyEarnings Overview Summary & Pattern Based Trade Signal System - DonanımHaber
Will AEON Biopharma Inc. Class stock sustain dividend payoutsJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - DonanımHaber
Will AEON Biopharma Inc. stock recover faster than marketMarket Sentiment Review & Smart Allocation Stock Reports - DonanımHaber
What insider trading reveals about AEON Biopharma Inc. stockPortfolio Update Summary & AI Enhanced Market Trend Forecasts - Улправда
AEON Biopharma Earnings Notes - Trefis
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong - The Manila Times
AEON Biopharma IncExchange to Eliminate Ov - 富途牛牛
AEON Biopharma announces execution of exchange agreement with Daewoong Pharmaceutical - MSN
Aeon Biopharma announces execution of exchange agreement with Daewoong - marketscreener.com
AEON Biopharma Announces Exchange Agreement with Daewoong - TipRanks
AEON Biopharma announces exchange agreement with Daewoong - MSN
AEON Biopharma signs Daewoong note exchange with equity and warrants | AEON SEC FilingForm 8-K - Stock Titan
AEON Biopharma (NYSE: AEON) agrees Daewoong swap cutting over 90% of debt - Stock Titan
AEON and Daewoong finalize $15 million debt-to-equity exchange deal - Investing.com
Aeon Biopharma Continues Push to Commercialization - Orange County Business Journal
AEON Biopharma (AEON) Price Target Decreased by 15.28% to 6.22 - Nasdaq
AEON Biopharma Releases New Corporate Presentation - The Globe and Mail
How AEON Biopharma Inc. Class stock performs in volatility spikesQuarterly Market Review & Fast Gain Stock Trading Tips - Newser
Can AEON Biopharma Inc. Class stock retain market dominanceJuly 2025 Summary & Trade Opportunity Analysis Reports - Newser
AEON Biopharma : Corporate Presentation - marketscreener.com
AEON Biopharma (NYSE: AEON) releases new investor Corporate Presentation - Stock Titan
AEON Biopharma, Inc. Releases Corporate Presentation on Biosimilar Development - TradingView
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight - GlobeNewswire Inc.
Aeon Biopharma Reports Positive Data and Strategic Moves - MSN
Aeon Secures Funding As FDA Sets New Date For Botox Biosimilar Review - Citeline News & Insights
Check out these key findings about AEON Biopharma Inc (AEON) - Setenews
AEON Biopharma Inc. Stock (AEON) Financials Data
There is no financial data for AEON Biopharma Inc. (AEON). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Cap:
|
Volume (24h):